Skip to Content

Tremtex: Neurostimulation Devices for the Management of Parkinson’s Disease Symptoms

Team Members:
  • David Blumenstyk
  • Ian Graham
  • Shruthi Rajan
  • Erin Reisfeld
  • Melody Tan
  • Zoltan Mari, MD
  • Reza Shadmehr, PhD
  • Yousef Salimpour, PhD
  • Robert Atkinson, JD
  • Gad Alon, PT, PhD
  • Neil Rothman, PhD
  • Youseph Yazdi, PhD, MBA
  • Soumyadipta Acharya, MD, PhD
  • Paul Fearis
  • Lawrence Aronhime, MBA
  • Aditya Polsani
  • Pratik Patel
  • William Anderson, MD, PhD
  • Kristen Bowsher


Tremtex is working in conjunction with clinical and research partners at the Johns Hopkins School of Medicine to develop an intervention to help Parkinson’s disease patients manage their debilitating motor symptoms. Parkinson’s disease is an incurable, neurodegenerative disorder that affects more than 1 million people in the United States and 7 million people worldwide. The standard of care for Parkinson’s disease is medication; however, the effectiveness of medication wanes as the disease progresses. Another option for patients in advanced stages of the disease is deep brain stimulation, an expensive and invasive surgical procedure with strict eligibility criteria. This leaves a significant number of patients without an effective intervention.

Tremtex is addressing this gap by providing a low-risk solution for patients whose symptoms are undermanaged with existing interventions. The team has designed STIMband, a noninvasive electrical stimulation device, which delivers low and safe doses of transcranial direct current stimulation, to the motor cortices of the brain. The result is the reduction of motor symptoms, including tremors, and improved mobility. STIMband has been designed to ensure patient safety and usability, allowing patients to receive treatment within the comfort of their homes.

Read the Johns Hopkins University privacy statement here.